Phacilitate Leaders World 

Features, Workshops & Networking Agenda

Loading

Briefing with Invetech - Now it's getting serious – assured pathways to commercial manufacturing

24 Jan 2019
Jasmine
Briefings

Now it’s getting serious - assured pathways to commercial manufacturing. 

Today’s pathfinders discuss their vision for the coming era of industrialized cell therapy production

Facilitator
- David Hodl, Vice President, Business Development for Cell Therapy

Panellist
- Vijay Chiruvolu,  VP of Global Process Development - Cell Therapy, Kite Pharma - A Gilead Sciences Company

- Randy Schweickart, Director of Engineering, Juno Therapeutics, Inc.

- Steve Goodman, Head of Drug Product Manufacturing, bluebird bio

 

 

Speakers
Randy Schweickart, Director of Engineering - Juno Therapeutics, Inc.
Vijay Chiruvulu, VP of Global Process Development - Cell Therapy - Kite Pharma (A Gilead Company)
Steve Goodman , Head of Drug Product Manufacturing - bluebird bio
David Hodl, Vice President, Business Development for Cell Therapy - Invetech
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK